110 results about "Enoxolone" patented technology

A method for improving health conditions of mammals or livestock by feeding, to the mammals or livestock, a licorice extract including: (A) glycyrrhizic acid, a glycyrrhizic acid derivative, glycyrrhetinic acid, and / or a glycyrrhetinic acid derivative; (B) licorice saponins other than (A); and (C) licorice flavonoids; (B) including at least a licorice saponin H2, a licorice saponin G2, and macedonoside A, (C) including at least liquiritin apioside, isoliquiritin apioside, and isoliquiritin, where feeding is of 0.017 g / day / head or more of the licorice saponin H2, 0.002 g / day / head or more of the licorice saponin G2, and 0.002 g / day / head or more of the macedonoside A, 0.001 g / day / head or more of the liquiritin apioside, 0.001 g / day / head or more of the isoliquiritin apioside, and 0.001 g / day / head or more of the isoliquiritin.

The invention relates to a glabridin self-assembly inclusion with an ultra-small particle size as well as a preparation method and application thereof, and belongs to the technical field of cosmetics. The composition disclosed by the invention is prepared from the following components in parts by weight: 0.5 to 5 parts of glabridin, 10 to 30 parts of polyhydric alcohol, 0.4 to 6.5 parts of liquorice root carrier component, 1.5 to 3 parts of nonionic emulsifier A, 0.45 to 1.8 parts of nonionic emulsifier B and 53.7 to 87.15 parts of water, the liquorice carrier component comprises at least one of glycyrrhizic acid, ammonium glycyrrhizinate and glycyrrhetinic acid; the nonionic emulsifier A is a nonionic emulsifier of which the hydrophilic-lipophilic balance value HLB is greater than 9; and the nonionic emulsifier B is a nonionic emulsifier with a hydrophilic-lipophilic balance value HLB of 2-4. The glabridin self-assembly inclusion disclosed by the invention is smaller in particle size, good in wrapping performance and good in targeting property; the stability is good, glabridin wrapping does not separate out, and the transdermal absorption rate is higher.

The invention provides glycyrrhizic acid / glycyrrhetinic acid-triethanolamine composite hydrogel as well as a preparation method and application thereof, and belongs to the technical field of preparation of biological medicine carriers and composite materials. According to the invention, glycyrrhizic acid or glycyrrhetinic acid is taken as a raw material, triethanolamine is taken as a cross-linking regulating agent, and the composite hydrogel with stable mechanical properties, high drug loading efficiency and anti-inflammatory synergistic activity is prepared through a mild physical and chemical cross-linking reaction; the preparation process of the composite hydrogel does not need a toxic cross-linking agent, the reaction condition is mild, the raw materials are cheap and easy to obtain, and large-scale production can be realized; the composite hydrogel presents a multi-group ionic bond cross-linked structure, can be used as a carrier of a pH responsive drug, and has good practicability.

The invention discloses an alveolar macrophage glycyrrhetinic acid liposome and a preparation method thereof, and belongs to the field of biological medicines. The surface of glycyrrhetinic acid lipidosome is modified with alveolar macrophage targeting molecules, so that the lipidosome can specifically target M1 alveolar macrophages induced by lipopolysaccharide serving as a main component of the outer wall of gram-negative bacteria, entrapped glycyrrhetinic acid is ingested by the alveolar macrophages, M2 polarization is specifically induced, and the specific targeting effect is achieved. Lung inflammatory injury caused by gram-negative bacteria is reduced, lung tissue injury and fibrosis caused by excessive inflammation are prevented, and great significance is achieved for pneumonia caused by gram-negative bacteria.

The application discloses application of glycyrrhetinic acid as a feed additive to improve the egg laying rate of laying hens. In the laying hen diet of the application, only glycyrrhetinic acid is added, and no chemical synthetic drugs and hormone substances are added, so that the safety of chicken and egg products is guaranteed from the source. The application fully considers the feed cost in application and feed preparation problems, selects glycyrrhetinic acid with low cost, fully plays the medicinal value of traditional Chinese medicinal materials, and the glycyrrhetinic acid is a natural plant extract, has no toxic side effects on laying hens, meanwhile, the preparation and purification method of the glycyrrhetinic acid is simple, the market price is low, and the glycyrrhetinic acid has the advantages of large-scale application.

The present invention aims to provide a scalp composition, such as a hair growth agent or hair restoration agent, comprising at least glycyrrhetinic acid or a salt thereof, polyoxyethylene hydrogenated castor oil, and ethanol, wherein the composition does not cause the precipitation of precipitates over time. [Solution] A scalp composition that does not produce precipitates and / or insoluble matter can be provided by comprising (A) glycyrrhetinic acid or a salt thereof, (B) polyoxyethylene hydrogenated castor oil, (C) ethanol, and (D) one or more selected from the group consisting of 1,3-butylene glycol and polyethylene glycol monooleate.

The preparation method comprises the following steps: directionally enriching glycyrrhizic acid and liquiritin through a four-step process of temperature-controlled countercurrent extraction, acid precipitation and enrichment, membrane filtration and resin separation, and synchronously removing polysaccharides, pectin and bitter substance glycyrrhetinic acid residues. Compared with a traditional method, the method has the triple advantages that (1) the sweetness enhancing function is achieved, and glycyrrhizic acid and liquiritin cooperate to achieve 2-10 times of wine sweetness adjustment; 2) the stability is prominent, and the turbidity is only increased by 2NTU (25NTU in the traditional process) through 30-day acceleration test; 3) the sensory quality is optimized, and the sensory score of the blended wine body reaches 92 (the medicinal aroma and the wine aroma are harmonious and precipitate-free).

The invention relates to a traditional Chinese medicine composition which comprises more than 1.09 permillage of ephedrine hydrochloride, more than 0.86 permillage of pseudoephedrine hydrochloride, more than 0.17 permillage of peiminine, more than 0.03 permillage of peimine, more than 0.17 permillage of chrysin-7-O-glucuronide, more than 0.002 permillage of glycyrrhetinic acid, more than 11.87 permillage of amygdalin and more than 0.01 permillage of neotuberostemonine. The oral liquid is prepared from more than 2.16 per mill of glycyrrhizic acid, more than 1.97 per mill of oroxylin A, more than 1.97 per mill of oroxylin B, more than 1.23 per mill of liquiritin, more than 0.59 per mill of apiose liquiritin, more than 0.55 per mill of baicalin, more than 0.23 per mill of chlorogenic acid, more than 0.18 per mill of praeruptorin A, more than 0.15 per mill of wild melanosin, more than 0.14 per mill of methyephedrine hydrochloride, more than 0.13 per mill of isoliquiritin, more than 0.13 per mill of neochlorogenic acid and more than 0.13 per mill of cryptochlorogenic acid. The composition is prepared from more than 0.10% of peimine, more than 0.08% of baicalein, more than 0.05% of praeruptorin B, more than 0.04% of praeruptorin C, more than 0.011% of xanthoxylin and more than 0.0006% of formononetin.

The present application relates to the field of detection, and particularly relates to a hybridoma cell strain XXML-2G11A7, a preparation method and application thereof; the hybridoma cell strain XXML-2G11A7 has a preservation number of CGMCC NO: 46139, a preservation date of November 21, 2024, and a preservation unit of China General Microbiological Culture Collection Center, and a preservation unit address of No. 3, Institute of Microbiology, Chinese Academy of Sciences, 1st North Chenxi Road, Chaoyang District, Beijing; the antibody secreted by the hybridoma cell strain XXML-2G11A7 of the present application can specifically detect enoxolone, has high sensitivity and good accuracy.

The invention relates to a chemical control agent suitable for liquorice and screening of the chemical control agent. The chemical control agent is composed of uniconazole. The invention also provides application of uniconazole in preparation of the glycyrrhiza chemical control agent, and optionally, the chemical control agent has one or more of the following applications: a, reducing the area of glycyrrhiza leaves; b, increasing the chlorophyll content of licorice leaves; c, thickening the roots of the licorice roots; d, reducing the height of licorice plants; e, increasing underground biomass of liquorice; f, increasing the content of total flavonoids in liquorice roots; and g, increasing the content of one or more of glycyrrhizic acid, liquiritigenin, isoliquiritigenin and glycyrrhetinic acid of the licorice roots. The invention further provides a method for improving lodging resistance of liquorice. The method comprises the step of applying uniconazole to the liquorice. The invention provides a thought and a method for effectively controlling the plant height of liquorice and improving the economic benefit of liquorice cultivation, and lays a foundation for field management and sustainable development of subsequent liquorice cultivation.

The present invention provides a gel composition and an oil-in-water composition that have a strong barrier function.　The gel composition comprises: one or more first compounds, which are represented by polyoxyethylene phytosterols; one or more second compounds, which are represented by polyethylene glycol distearate; one or more third compounds, which are represented by polyoxyethylene alkyl ethers; and one or more fourth compounds selected from the group consisting of ascorbic acid and salts thereof, ascorbic acid monoesters, ascorbic acid diesters, tocopherols and esters thereof, glycyrrhetinic acid and esters and salts thereof, and betamethasone and esters thereof.

The invention discloses a preparation method and application of a hyaluronic acid-glycyrrhetinic acid and hyaluronic acid-ferulic acid conjugate nanoparticle drug delivery system, and relates to the technical field of biological pharmacy. The key points of the technical scheme are as follows: GA and FA are respectively connected with HA by using adipic acid dihydrazide as a connexon; and the hyaluronic acid-glycyrrhetinic acid and hyaluronic acid-ferulic acid polymer prodrugs are synthesized. An in-vitro release result shows that when the NPs are exposed in a physiological medium with slightly acidic pH, the drug release rate is higher than that in a blood environment with pH of 7.4. And the drug release rate and the drug release amount of the nanoparticles are superior to those of single drug release. The HA-ADH-GA and the HA-ADH-FANPs both have relatively low toxicity in vitro and a good effect of resisting the influenza A virus H1N1. Compared with the HA-ADH-FANPs, the HA-ADH-GANPs has the advantage that the HA-ADH-GANPs has a better protection effect on a mouse infected with the H1N1-UI182 in vivo.

The application discloses a lactobacillus crispatus based on multiple targets to realize anti-aging effect and application of transformation of glycyrrhiza for efficiency enhancement, and belongs to the technical field of microorganisms and the technical field of medicine. The lactobacillus crispatus CCFM1362 provided in the application can ferment glycyrrhiza extract, can improve the content of glycyrrhizic acid, hemiglycyrrhizin isoflavone B, naringenin chalcone and other substances, can enhance the efficacy of glycyrrhiza extract, and can realize the effect of multiple targets for anti-aging, and the specific embodiments are as follows: (1) the content of beta-galactosidase in liver tissue is inhibited; (2) the level of aging-related secretory phenotype in liver tissue is reduced; (3) the Nrf2 related pathway is activated, and the level of oxidative stress is reduced; (4) the NF-kappa B related pathway is activated, and the level of chronic inflammation is reduced. Therefore, the lactobacillus crispatus CCFM1362 and the glycyrrhiza extract have great application prospect in the production of anti-aging products.

The present invention relates to a self-assembled inclusion of glabridin with an ultra-small particle size, a preparation method, and an application thereof, and belongs to the field of cosmetic technology. The composition of the present invention comprises the following components in parts by weight: 0.5-5 parts of glabridin, 10-30 parts of polyol, 0.4-6.5 parts of a licorice carrier component, 1.5-3 parts of a nonionic emulsifier A, 0.45-1.8 parts of a nonionic emulsifier B, and 53.7-87.15 parts of water; the licorice carrier component comprises at least one of glycyrrhizic acid, ammonium glycyrrhizate, and glycyrrhetinic acid; the nonionic emulsifier A is a nonionic emulsifier with a hydrophilic-lipophilic balance value (HLB) greater than 9; the nonionic emulsifier B is a nonionic emulsifier with a hydrophilic-lipophilic balance value (HLB) of 2-4. The self-assembled inclusion of glabridin of the present invention has a smaller particle size, good encapsulation performance, and good targeting; it has good stability, the glabridin encapsulation does not precipitate, and the transdermal absorption rate is higher.

The invention relates to application of azole drugs in preparation of antifungal drugs, and belongs to the technical field of research and development of antifungal drugs. According to the application of the glycyrrhetinic acid combined with the azoles in preparation of the antifungal drugs, the glycyrrhetinic acid combined with the itraconazole, the voriconazole and the posaconazole shows a good synergistic effect or antagonistic effect on aspergillus, ectobottle dermatitis, candida and cryptococcus neoformans, and the application of the glycyrrhetinic acid combined with the itraconazole, the voriconazole and the posaconazole in preparation of the antifungal drugs is disclosed. And a research and development direction is provided for preparing medicines for resisting aspergillus, ectobottle dermatitis, candida and cryptococcus neoformans.

Provided are a cosurfactant-free microemulsion encapsulating glycyrrhetinic acid, a preparation method therefor, and use thereof. The cosurfactant-free microemulsion comprises carvacrol / thymol, a fatty acid, a nonionic surfactant, and water. Based on the mass percentage of the raw materials, the glycyrrhetinic acid accounts for 0.1-5%, the carvacrol / thymol accounts for 0.1-5%, the fatty acid accounts for 0.1-10%, the nonionic surfactant accounts for 1-30%, and the balance is made up to 100% with water. Carvacrol / thymol not only increases the solubility of glycyrrhetinic acid, but also promotes the transdermal absorption of glycyrrhetinic acid, and is a cosmetic composite efficacy composition having antioxidant, anti-inflammatory, and antibacterial effects.

The application discloses a kind of 18 beta-glycyrrhetinic acid ester derivatives with PPAR gamma agonistic activity and its preparation method and application, belongs to chemical pharmaceutical technical field, specifically related to a kind of 18 beta-glycyrrhetinic acid ester derivatives molecules and its application as PPAR gamma agonist in antitumor aspect.The application uses Steglich esterification reaction, with dicyclohexyl carbodiimide and 4-dimethylaminopyridine as catalyst, 18 beta-glycyrrhetinic acid is reacted with different types of carboxylic acid, and a kind of novel 18 beta-glycyrrhetinic acid ester derivative molecules are obtained by semi-synthesis;Computer simulation molecular docking and in vitro enzyme activity experiment show that this kind of molecule can be used as PPAR gamma agonist and play significant antitumor activity.

A composition for relieving hangovers and protecting the liver, made from the following raw materials in the indicated weight ratios: 3-20 parts of kudzu root extract, 2-20 parts of Japanese raisin tree fruit extract, 1-12 parts of N-acetylcysteine, 1-12 parts of L-ornithine, 1-15 parts of L-glutamine, 0.2-8 parts of glycyrrhetinic acid glycyrrhiza extract, 0.05-5 parts of curcumin, 0.005-0.5 parts of piperine, 0.5-10 parts of vitamin C, 0.01-2 parts of B vitamins complex, 0.1-8 parts of electrolyte salts, and 1-25 parts of honey or oligosaccharides.

The present invention belongs to the field of biomedicine and specifically discloses the use of glycyrrhetinic acid or glycyrrhetinic acid liposomes in the preparation of a drug for protecting against abdominal aortic aneurysms. It reveals that glycyrrhetinic acid can effectively ameliorate the mortality of mice following aortic rupture caused by Ang II treatment, significantly improve the degradation of the aortic elastic fiber layer caused by Ang II treatment, and promote the polarization of lipopolysaccharide (LPS)-induced macrophages toward the M2 type. Intervention with glycyrrhetinic acid before Ang II treatment can alleviate the occurrence of Ang II-induced abdominal aortic aneurysms and improve the survival rate of mice, indicating that glycyrrhetinic acid can be used to prepare a drug for alleviating abdominal aortic aneurysms. Furthermore, the present invention improves the solubility and bioavailability of glycyrrhetinic acid by encapsulating it in liposomes. At the same time, after glycyrrhetinic acid is encapsulated using nanotechnology, its dosage can be effectively controlled, further improving and enhancing the therapeutic effect of glycyrrhetinic acid.

The application provides a pharmaceutical composition for treating rheumatoid arthritis, which is composed of paeoniflorin, glycyrrhizin, glycyrrhizic acid and glycyrrhetic acid in a weight ratio of (4.5-7.5):(0.4-1.8):(1.8-4.3):(22-40). The pharmaceutical composition can significantly inhibit the proliferation of fibroblast-like synoviocytes, reduce the secretion of inflammation-related factors (TNF-alpha, IL-1beta, IL-6 and COX-2), regulate the expression of TNF-alpha / NF-kappaB signal pathway-related proteins, and has a significant curative effect on rheumatoid arthritis.

The main purpose set by the present inventors is to provide a technology for suppressing inflammation particularly in aged tissue in the oral cavity.　The present inventors have discovered that it is possible to suppress inflammation particularly in aged tissue in the oral cavity by an oral cavity composition that contains β-glycyrrhetinic acid and at least one selected from the group consisting of retinol acetate, retinol, all-trans-retinoic acid, ascorbic acid, cobalamin, calciferol, anthraquinone, L-histidine, methylhesperidin, and chemically possible salts thereof.

The invention discloses a method for preparing glycyrrhetinic acid under the assistance of mechanochemistry, which comprises the following specific operation processes: adding a pretreated liquorice raw material and a grinding aid into a ball milling tank of a ball mill, adding zirconium oxide beads to carry out co-grinding reaction, separating a product from the zirconium beads after the reaction is finished, and drying to obtain the glycyrrhetinic acid. And heating and hydrolyzing the product and an ethanol solution to obtain glycyrrhetinic acid. A mechanochemical one-step method is innovatively adopted, glycyrrhetinic acid can be efficiently prepared, the tedious steps of firstly extracting glycyrrhizic acid and then carrying out hydrolysis in a traditional process are thoroughly abandoned, glycyrrhetinic acid is prepared through mechanochemical assistance, and under the action of high-energy mechanical force, a grinding auxiliary agent and glycyrrhizic acid are promoted to be efficiently combined to promote glycyrrhizic acid hydrolysis; the preparation time is greatly shortened; and the generation of acid waste liquid is greatly reduced.

The invention belongs to the technical field of biology and new medicine, and discloses a preparation method of acoustic resonance driven glycyrrhizic acid nano-composite responsive gel, glycyrrhizic acid is used as a drug carrying system, berberine, ursolic acid, baicalein, luteolinin, curcumin, baicalin or ginsenoside Rh2 is used as a water-insoluble natural small molecule drug, and the acoustic resonance driven glycyrrhizic acid nano-composite responsive gel is prepared. Glycyrrhizic acid is an amphiphilic compound composed of one molecule of glycyrrhetinic acid and two molecules of glucuronic acid, a hydrophobic cavity can be formed in a water environment to wrap the water-insoluble natural small molecule medicine, a glycyrrhizic acid nano-composite solution is formed, and meanwhile the solubility of the water-insoluble natural small molecule medicine such as baicalein is improved.

The invention discloses a high-efficiency targeted anti-hepatic fibrosis oral nano drug delivery system and a preparation method thereof. According to the system, a sesquiterpene lactone component, namely lettuce lactone (LC), in Xinjiang traditional liver protection medicinal material cichorium glandulosum is used as a medicine core, and although the lettuce lactone has a good anti-fibrosis effect, the lettuce lactone (LC) has the problems of poor water solubility, high first-pass metabolism and the like. Therefore, 18 beta-glycyrrhetinic acid modified silicon-based hybrid micelles (LC-FS-G) are studied and constructed, the liver targeting property of glycyrrhetinic acid and a silicon-based cross-linked structure are utilized to enhance the stability, and drug release is responded in a glutathione (GSH) high expression environment by virtue of a disulfide bond. The particle size of the obtained micelle is uniform (27.83 nm), the encapsulation efficiency reaches 95.05%, and the drug loading rate is 10.62%. The system is slowly released in gastric juice (48h release lt); 50%), and the gt can be quickly released in a high GSH environment (36h release gt; 87%), and the liver fibrosis process can be reversed by regulating and controlling a TGF-beta / Smad pathway. According to the strategy, physicochemical and metabolic restrictions of LC are overcome, and a new way with high efficiency and low toxicity is provided for oral nano targeted therapy of hepatic fibrosis.

The application belongs to the technical field of medicine, and specifically discloses a glycyrrhetinic acid injectable hydrogel as well as a preparation method and application thereof. The preparation method of the glycyrrhetinic acid injectable hydrogel comprises the following steps: glycyrrhetinic acid and choline hydroxide are added into pure water, heated and stirred to fully react, and a mixed solution is obtained; the mixed solution is first spin-evaporated and then vacuum-dried to obtain glycyrrhetinic acid-choline; the glycyrrhetinic acid-choline is added into pure water, heated to completely dissolve and cooled at room temperature to form an injectable hydrogel. The hydrogel is used for preparing an antitumor drug in an injectable dosage form. In the application, the glycyrrhetinic acid and the choline hydroxide are self-assembled into a hydrogel with a three-dimensional network microstructure by losing one molecule of water without adding any cross-linking agent and organic solvent. The hydrogel can quickly recover to the original gel state after injection, and the problems of low drug loading, low bioavailability and difficult degradation existing in the prior art are solved.

This invention relates to the field of traditional Chinese medicine technology, specifically to a composition for clearing heat and detoxifying, protecting the liver and improving eyesight, its pharmaceutical preparation and application. The raw materials of the composition, by weight, include the following components: 10-30 parts ursodeoxycholic acid, 1-5 parts chenodeoxycholic acid, 5-15 parts Lycium barbarum polysaccharide, 5-18 parts betaine, 1-5 parts glycyrrhizic acid, 0.2-5 parts glycyrrhetinic acid, and 1-5 parts glycyrrhizin. This invention combines these components to achieve the effects of clearing heat and detoxifying, protecting the liver and improving eyesight. Pharmacological experiments have demonstrated that it has significant antipyretic effects, prevents and treats eye fatigue, and improves acute liver injury.

The invention discloses an intestinal barrier repairing agent based on glycyrrhizic acid derivatives and a preparation method thereof, and relates to the field of pharmaceutical preparations, the intestinal barrier repairing agent comprises a repairing unit, a regulating unit and a delivery system for controlled release; the repairing unit comprises 18 beta-glycyrrhetinic acid and glycyrrhizol; the regulating unit comprises probiotics and prebiotics; according to the intestinal barrier repairing agent based on the glycyrrhizic acid derivative and the preparation method of the intestinal barrier repairing agent, through sequential release design of firstly adjusting a microenvironment and then executing repairing, the bottlenecks of disordered component release and insufficient synergy in the prior art are overcome; the colon programmed release logic of probiotic pilot colonization and subsequent repair of licorice active ingredients is established for the first time, and the physiological healing rule of the intestinal barrier is better met; by adopting a physically mixed double-layer heterogeneous pellet structure, not only is the activity of probiotics ensured, but also the efficient delivery of insoluble drugs is realized, and the process feasibility is high.

The invention relates to the technical field of microorganisms, and particularly discloses application of acetobacter orientalis T1-1 in preparation of glycyrrhetinic acid. The invention discloses a high-yield strain of glycyrrhetinic acid, namely acetobacter orientalis T1-1, and the yield of the glycyrrhetinic acid can reach 1.62%-2.09% after the glycyrrhiza is fermented by the acetobacter orientalis T1-1. Compared with fermentation of a control strain, the yield of a target product can be increased by 67%-386%. On the basis, the invention provides the preparation method of the glycyrrhetinic acid, the preparation method has the advantages of short fermentation period, high target product yield, low energy consumption, mild preparation conditions and easiness in control, and can be used for green, efficient and industrial production of the glycyrrhetinic acid, and the prepared glycyrrhetinic acid can be further applied to the fields of foods, medicines, daily chemicals and the like.

The invention discloses a skin cell nucleus nutritional agent containing traditional Chinese medicine components and capable of improving ichthyosis and a preparation method, and relates to the technical field of preparation of skin cell nucleus nutritional agents. Comprising the following raw materials: modified vitamin A propionate, a traditional Chinese medicine extract, modified hydrogenated lecithin, squalane, beewax, stearyl alcohol, vaseline, glycerin, sodium hyaluronate, beta-glucan, propylene glycol, potassium cetyl phosphate, a preservative, allantoin, deionized water, triethanolamine and a lipid solvent. According to the invention, the modified tretinoin propionate is added, and the modified tretinoin propionate is subjected to double-grafting modification through glycyrrhetinic acid-hyaluronic acid oligosaccharide and is gently combined with a basal cell tretinoin receptor in a targeted manner, so that excessive proliferation of basal cells can be inhibited, and normal differentiation of keratinocytes can be promoted; wherein the glycyrrhetinic acid component can resist inflammation, relieve and reduce self-irritation, and the hyaluronic acid oligosaccharide can improve targeting and transdermal efficiency, avoid light / oxygen degradation and provide a core regulation effect for restoring the 28-day metabolic cycle of basal cells.

Composition, in particular pharmaceutical composition, in the form of a fixed dosage (solid dosage form) for sucking and / or chewing, preferably for sucking, in particular lozenge, preferably for use in the prophylactic and / or therapeutic topical (local) treatment of inflammatory diseases of the mouth and throat, wherein the composition contains an effective, in particular pharmaceutically and / or therapeutically effective, amount of an active ingredient preferably suitable and / or effective for the topical (local) treatment of inflammatory diseases of the mouth and throat, in particular with antiseptic and / or antimicrobial properties, preferably with antibacterial and / or antiviral and / or antifungal properties, wherein the active ingredient is incorporated and / or embedded in a solid matrix, wherein the composition, in particular the solid dosage form and / or the matrix, releases the active ingredient upon topical (local) application and / or use, preferably by sucking and / or chewing, preferably by sucking, in the oral and pharyngeal cavity; wherein the active ingredient is octenidine, in particular in the form of a pharmaceutically compatible and / or physiologically acceptable salt or ester, preferably in the form of a pharmaceutically compatible and / or physiologically acceptable salt, particularly preferably octenidine dihydrochloride; and wherein the composition, in particular the solid dosage form and / or the matrix, furthermore and / or additionally contains at least one further ingredient (a) and / or (b), in particular (a) and (b), wherein the at least one further ingredient (a) and / or (b) is selected from the group of (a) Flavor modulators, in particular selected from the group of the following components (i), (ii) and / or (iii): (i) Bitter (taste) masking agents, in particular selected from the group consisting of bitter taste receptor antagonists, preferably 4-(2,2,3-trimethylcyclopentyl)butanoic acid, and saponins, preferably glycyrrhizic acid (glycyrrhizin) and its salts or esters and / or glycyrrhetinic acid (glycyrrhetin) and its salts or esters, complexing agents, in particular cyclodextrins, and combinations or mixtures thereof, (ii) Bitter substances, in particular coffee extract and / or tea extract and / or their respective bitter substances, preferably coffee extract and / or its bitter substances, (iii) preferably natural or nature-identical (aroma) oils and / or essential oils, in particular with antiseptic and / or antimicrobial properties, preferably with antibacterial, antifungal and / or antiviral properties, in particular selected from the group of anise oils, in particular star anise oil, peppermint oil, eucalyptus oil, lavender oil, tea tree oil, chamomile oil, clove oil, rosemary oil, caraway oil, cinnamon oil, sage oil and fennel oil, as well as combinations or mixtures thereof; in particular wherein the ingredient (a) and / or the flavor modulator comprises a combination of at least two different components (i), (ii) and / or (iii), preferably a combination of components (i), (ii) and (iii); (b) Acidulants, in particular saliva-stimulating and / or flavor-enhancing acidulants, preferably acidulants authorized under pharmaceutical and / or food law and / or acidulants authorized as pharmaceutical additives and / or food additives, in particular selected from the group of tartaric acid and its salts, in particular sodium tartrate, sodium potassium tartrate (Rochelle salt) and calcium tartrate, citric acid and its salts, metatartaric acid, fumaric acid, ascorbic acid, phosphoric acid and its salts, stannous chloride, in particular tin(II) chloride, malic acid, lactic acid, adipic acid, succinic acid and other pharmaceutically compatible and / or physiologically acceptable organic acids and their salts, as well as their combinations or mixtures.